The host STING pathway at the interface of cancer and immunity
Open Access
- 1 July 2016
- journal article
- review article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 126 (7), 2404-2411
- https://doi.org/10.1172/jci86892
Abstract
A major subset of human cancers shows evidence for spontaneous adaptive immunity, which is reflected by the presence of infiltrating CD8+ T cells specific for tumor antigens within the tumor microenvironment. This observation has raised the question of which innate immune sensing pathway might detect the presence of cancer and lead to a natural adaptive antitumor immune response in the absence of exogenous infectious pathogens. Evidence for a critical functional role for type I IFNs led to interrogation of candidate innate immune sensing pathways that might be triggered by tumor presence and induce type I IFN production. Such analyses have revealed a major role for the stimulator of IFN genes pathway (STING pathway), which senses cytosolic tumor–derived DNA within the cytosol of tumor-infiltrating DCs. Activation of this pathway is correlated with IFN-β production and induction of antitumor T cells. Based on the biology of this natural immune response, pharmacologic agonists of the STING pathway are being developed to augment and optimize STING activation as a cancer therapy. Intratumoral administration of STING agonists results in remarkable therapeutic activity in mouse models, and STING agonists are being carried forward into phase I clinical testing.Keywords
This publication has 91 references indexed in Scilit:
- Deregulation of STING Signaling in Colorectal Carcinoma Constrains DNA Damage Responses and Correlates With TumorigenesisCell Reports, 2015
- Type I interferons in anticancer immunityNature Reviews Immunology, 2015
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- STING-dependent cytosolic DNA sensing pathwaysTrends in Immunology, 2014
- Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic AcidPublished by The American Association of Immunologists ,2013
- Cyclic di-GMP: the First 25 Years of a Universal Bacterial Second MessengerMicrobiology and Molecular Biology Reviews, 2013
- Regulation of the Antimicrobial Response by NLR ProteinsImmunity, 2011
- Trex1 Prevents Cell-Intrinsic Initiation of AutoimmunityCell, 2008
- A critical function for type I interferons in cancer immunoeditingNature Immunology, 2005
- Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian CancerNew England Journal of Medicine, 2003